The main role of its injection is to treat and prevent diseases caused by infections caused by Mycoplasma, Pasteurella and Erysipelas, as well as Pneumococcus, Staphylococcus, etc. Especially when children are seriously ill with a cold, they are more likely to cause mycoplasma infection and pneumococcal infection, and at the same time, they will have repeated high fever. Therefore, similar infection problems must be paid attention to and receive effective treatment in time. If a condition caused by similar symptoms occurs, it is recommended to actively cooperate with the doctor for treatment. At the same time, pay attention to the lightness of the diet, avoid eating some spicy and stimulating foods, drink more water, eat more fresh fruits and vegetables, and pay attention to more rest.
Company Profile
Ningxia Taiyixin Biotechnology Co., Ltd. was established in 2010 and is located in Helan County Industrial Park (Nuanquan Area), Yinchuan City, Ningxia, with a registered capital of 768 million yuan, a planned land area of 3,300 mu, and a total investment of nearly 6 billion yuan. More than 1900 people. It is mainly committed to the research and development, production and sales of biomedicine, bio-veterinary drugs and bio-pesticides, and will strive to become a large-scale pharmaceutical enterprise with sustainable development of "safety, technological innovation, environment-friendly, quality and efficiency". The company has successively obtained the "National High-tech Enterprise" certificate, and has been included in the "National Industrial Internet Integration Application Pilot Demonstration Enterprise", "China's Foreign Trade Export Leading Index Sample Enterprise", "Ningxia Hui Autonomous Region Industrial Leading Enterprise" and "The District's Industrial Steady Growth" It ranks among the “Enterprise with Outstanding Contribution to Work” and is the “Biomedical Innovation Center” of the autonomous region. During the new crown epidemic in 2020, it was rated as "Key Enterprise for Epidemic Prevention and Control" by the Ministry of Industry and Information Technology of the People's Republic of China, and was rated as "Key Manufacturer of Epidemic Prevention Products" by the Department of Industry and Information Technology of the Autonomous Region. At present, the products have been sold to more than 120 countries and regions.